Articles published in Pulmonary & Respiratory Medicine have been cited by esteemed scholars and scientists all around the world.
Pulmonary & Respiratory Medicine has got h-index 20, which means every article in Pulmonary & Respiratory Medicine has got 20 average citations.
Following are the list of articles that have cited the articles published in Pulmonary & Respiratory Medicine.
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
Year wise published articles |
40 | 60 | 28 | 19 | 41 |
Year wise citations received |
150 | 168 | 194 | 193 | 169 |
| Journal total citations count | 1690 |
| Journal impact factor | 1.80 |
| Journal 5 years impact factor | 2.06 |
| Journal cite score | 6.21 |
| Journal h-index | 20 |
| Journal h-index since 2018 | 15 |
Argento AC, Murphy TE, Pisani MA, Araujo KL, Puchalski J (2015) Patient-centered outcomes following thoracentesis. Pleura 2: 2373997515600404. |
|
DeBiasi EM, Pisani MA, Murphy TE, Araujo K, Kookoolis A, et al. (2015) Mortality among patients with pleural effusion undergoing thoracentesis. European Respiratory Journal 46: 495-502. |
|
El-Shafey BI, El-Bedewy MM, Mostafa T, Attia M (2015) Serum resistin level in obstructive sleep apnea patients complicated with cardiac diseases, diabetes mellitus or renal impairment. Egyptian Journal of Chest Diseases and Tuberculosis 64: 129-135. |
|
Basem I, El-Bedewy MM, Mostafa T, Attia M. Serum resistin level in obstructive sleep apnea patients complicated with cardiac diseases, diabetes mellitus or renal impairment. |
|
Vijayalakshmi T, Stephen S, Nithyalakshmi J, Sumathi G, Selvi R, Jayalakshmi G. Detection of Diabetes In Smear Positive Pulmonary Tuberculosis Patients Attending Tertiary Care Teaching Hospital, Tamilnadu, India. |
|
Linguissi LS, Vouvoungui CJ, Poulain P, Essassa GB, Kwedi S, et al. (2015) Diagnosis of smear-negative pulmonary tuberculosis based on clinical signs in the Republic of Congo. BMC research notes 8: 804. |
|
Workneh MH, Bjune GA, Yimer SA (2016) Diabetes mellitus is associated with increased mortality during tuberculosis treatment: a prospective cohort study among tuberculosis patients in South-Eastern Amahra Region, Ethiopia. Infectious diseases of poverty 5: 22. |
|
SUPONE N, AVANCE U. valuación de. |
|
Ferguson GT, Karpel J, Bennett N, Clerisme-Beaty E, Grönke L, et al. (2017) Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. npj Primary Care Respiratory Medicine. 27: 7. |
|
Lee HW, Kim HJ, Lee CH (2016) The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and metaâ€Âanalysis. British Journal of Clinical Pharmacology. |
|
Maltais F, Kirsten AM, Hamilton A, De Sousa D, Voss F, et al. (2016) Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies. Respiratory Research 17: 77. |
|
Coupe B, Griffiths AL, Davies GA (2016) Drugs That Act on the Respiratory Tract. Side Effects of Drugs Annual 38: 153-164. |
|
Paul MO, Tony D, Beck E, Gahlemann M, Hart L, et al. (2015) Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting. sub. 2-agonist, in patients with asthma: results of a parallel-group study and a crossover study. Respiratory Research: 16:97. |
|
Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voss F, et al. Efficacy and safety of tiotropium+ olodaterol maintenance treatment in patients with COPD in the TOnaDO® and OTeMTO® studies: a subgroup analysis by age. International Journal of Chronic Obstructive Pulmonary Disease 11: 2701. |
|
Donohue JF (2014) Systematic review comparing LABA, olodaterol, and indacaterol: limitations. International journal of chronic obstructive pulmonary disease 9: 1331. |
|
Singh D, Gaga M, Schmidt O, Bjermer L, Grönke L, et al. (2016) Effects of tiotropium+ olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. Respiratory Research 17: 73. |
|
O’Byrne PM, D’Urzo T, Beck E, Fležar M, Gahlemann M, et al. (2015) Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β 2-agonist, in patients with asthma: results of a parallel-group study and a crossover study. Respiratory research 16: 97. |
|
Calzetta L, Ciaprini C, Puxeddu E, Cazzola M (2016) Olodaterol+ tiotropium bromide for the treatment of COPD. Expert review of respiratory medicine 10: 379-386. |
|
Ichinose M, Takizawa A, Izumoto T, Tadayasu Y, Hamilton AL, et al. (2015) Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease. International journal of chronic obstructive pulmonary disease 10: 1673. |
|
Beeh KM, LaForce C, Gahlemann M, Wenz A, Toorawa R, et al. (2015) Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma. Respiratory research 16: 87. |
|
Pulmonary & Respiratory Medicine received 1690 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 